Wang Y, Zhao Z, Rege SV, Wang M, Si G, Zhou Y, Wang S, Griffin JH, Goldman SA, Zlokovic BV (2016) 3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice, Nature Medicine Published online 22 August 2016. DOI: 10.1038/nm.4154


Amar AP, Griffin JH, Zlokovic BV (2015) Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. Front Cell Neurosci. 9, 344. PMID: PMC4556986


Mosnier LO, Zlokovic BV, Griffin JH (2014) Cytoprotective-Selective Activated Protein C Therapy for Ischaemic Stroke. J Thromb Haemost. 112 (5), 883-892. PMID: 25230930


Lyden P, Levy H, Weymer S, Pryor K, Kramer W, Griffin JH, Davis TP, Zlokovic B (2013) Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. Curr Pharm Des. 19 (42), 7479-7485. PMID: 24372304


Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV (2013) Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. Stroke 44 (12), 3529-3536. PMID: 24159062


Mosnier LO, Fernández JA, Davis TP, Zlokovic BV, Griffin JH (2013) Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant’s anticoagulant activity. J Thromb Haemost. 11 (11), 2059-2062. PMID: 24034518


Wang Y, Sinha RK, Mosnier LO, Griffin JH, Zlokovic BV (2013) Neurotoxicity of coagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells Mol Dis. e-pub ahead of print. PMID: 23541526


Guo H, Zhao Z, Yang Q, Wang M, Bell R, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV (2013) An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway. J. Neuroscience 33 (14), 6181-6190. Abstract


Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV (2013) Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Res. 1507, 97-104. PMID: 23438513


Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV (2012) An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tPA for ischemic stroke in rodents. Stroke 43 (9), 2444-2449. PMID: 22811462


Guo H, Wang Y, Singh I, Liu D, Fernandez JA, Chow N, Zlokovic BV (2009) Species-dependent neuroprotection by activated protein C mutants with reduced Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV (2009) Differential neuroprotection and risk for bleeding from activated protein C with varying degree of anticoagulant activity. Stroke 40(5), 1864-1869.


Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández J, Chow N, Griffin JH, Zlokovic BV (2009) Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur. J. Neurosci. 29, 1119-1130.


Walker, CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV (2010) Activated protein C analog with reduced anti-coagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Research 1347, 125-131. PMID: 20513369


Zlokovic BV, Griffin JH (2011) Activated protein C cytoprotective pathways and implications for stroke and neurological disorders. Trends in Neurosciences 34 (4), 1198-2009.


Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience 12, 723-738. PMID: 22048062


Williams PD, Zlokovic BV, Griffin JH, Pryor KE, Davis TP (2012) Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified  Activated Protein C for Stroke. Curr. Pharm. Des. 18 (27), 4215-4222. PMID: 22632606


Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino F, Stojanovic K, Cleveland DW, Zlokovic BV (2009) Activated protein C slows ALSlike disease by transcriptionally inhibiting SOD1 in motor neurons and microglial cells. J Clinical Investigation 119(11), 3437-3440.


Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, Griffin JH, Zlokovic BV (2004) Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41, 563-572. PMID: 14980205


Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, Zlokovic BV (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein Nat. Med. 10, 1379-1383. PMID: 15516929


Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH (2004) Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104, 1740-1744. PMID: 15178575


Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9, 338-342. PMID: 12563316


Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799-1805.